Edwards Lifesciences Corporation (NYSE:EW) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Edwards Lifesciences Corporation (NYSE:EW) have received an average rating of “Moderate Buy” from the twenty-eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, fifteen have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $96.8182.

EW has been the topic of a number of recent analyst reports. Truist Financial set a $92.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, December 5th. Oppenheimer downgraded shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Mizuho increased their price objective on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Royal Bank Of Canada raised their target price on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, December 5th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research note on Monday, November 3rd.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the transaction, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This represents a 16.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the transaction, the vice president owned 22,002 shares in the company, valued at $1,885,571.40. The trade was a 4.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 57,824 shares of company stock worth $4,863,323 over the last quarter. Company insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Edwards Lifesciences by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after purchasing an additional 365,581 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Edwards Lifesciences by 4.9% during the third quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after purchasing an additional 977,933 shares during the period. Bank of New York Mellon Corp raised its position in shares of Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after buying an additional 1,423,365 shares in the last quarter. Jennison Associates LLC raised its position in shares of Edwards Lifesciences by 19.6% in the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after buying an additional 2,287,783 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Edwards Lifesciences by 0.4% in the second quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock valued at $990,074,000 after buying an additional 45,555 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Down 0.9%

Shares of EW stock opened at $83.70 on Monday. Edwards Lifesciences has a 52-week low of $65.94 and a 52-week high of $87.89. The stock has a market cap of $48.57 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 3.19 and a beta of 0.95. The firm’s 50-day moving average is $84.99 and its 200-day moving average is $80.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.Edwards Lifesciences’s quarterly revenue was up 14.7% on a year-over-year basis. During the same quarter last year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Sell-side analysts predict that Edwards Lifesciences will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.